Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998710 · ClinicalTrials.gov registry record
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
A clinical trial of Homocystinuria Due to CBS Deficiency, sponsored by Travere Therapeutics.
- Recruiting
- Registry status
- 150
- Enrollment target
- 11
- Study locations
NCT02998710 is a study of Homocystinuria Due to CBS Deficiency that is actively recruiting participants, run by Travere Therapeutics. The registered enrollment target is 150 participants. The trial reports 11 study locations across 10 states.
The verdict
NCT02998710, a study of Homocystinuria Due to CBS Deficiency, is actively recruiting participants, sponsored by Travere Therapeutics.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
Conditions Studied
Study Locations (11)
Other
- Travere Investigational Site - Dublin
- Travere Investigational Site - Doha
California
- Travere Investigational Site - Virtual Site - Culver City
Colorado
- Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) - Aurora
District of Columbia
- Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) - Washington D.C.
Georgia
- Travere Investigational Site - Atlanta
Indiana
- Travere Investigational Site - Indianapolis
Massachusetts
- Travere Investigational Site - Boston
Pennsylvania
- Travere Investigational Site (Enrolling 1 to <5 Year-olds Only) - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-01 |
| Est. Completion | 2026-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998710
The ClinicalTrials.gov registry entry for NCT02998710 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Homocystinuria Due to CBS Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT02998710 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02998710 about?
NCT02998710 is a clinical study titled "Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)". The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
What is the current status of trial NCT02998710?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2017-01. Estimated completion is 2026-08.
What conditions does trial NCT02998710 study?
This clinical trial studies the following conditions: Homocystinuria Due to CBS Deficiency.
Who is sponsoring clinical trial NCT02998710?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02998710 being conducted?
This trial has 11 study locations across California, Colorado, District of Columbia, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.